More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$93.40B
EPS
45.21
P/E ratio
18.4
Price to sales
4.95
Dividend yield
0.416%
Beta
0.098446
Previous close
$930.67
Today's open
$938.51
Day's range
$901.53 - $948.11
52 week range
$591.52 - $991.73
show more
CEO
Leonard S. Schleifer
Employees
15410
Headquarters
Tarrytown, NY
Exchange
Nasdaq Global Select
Shares outstanding
103447859
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Why Regeneron (REGN) Might be Well Poised for a Surge
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks Investment Research • Nov 4, 2026

REGN vs. ILMN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research • Nov 4, 2026

UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC's ‘Final Trades'
On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, picked Cleveland-Cliffs Inc. (NYSE:CLF).
Benzinga • Nov 3, 2026

These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported better-than-expected third-quarter 2026 results. Regeneron reported adjusted earnings of $20.07 per share, up 70% year over year and above the analyst consensus estimate of $16.19.
Benzinga • Nov 2, 2026

Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Benzinga • Nov 2, 2026

Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m.
GlobeNewsWire • Nov 2, 2026

Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter
As of Nov. 2, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Benzinga • Nov 2, 2026

Regeneron: 3 Key Takeaways for Long-Term Investors
Dupixent global quarterly net sales grew 35% year over year to $6.5 billion. Total revenue increased 36% year over year to $5.1 billion.
The Motley Fool • Oct 31, 2026

What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call
Regeneron Pharmaceuticals NASDAQ: REGN reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT, EYLEA HD and LIBTAYO.
MarketBeat • Oct 30, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 30, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Regeneron Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.